

[Letterhead of the organisation]

Henning Gädeke
c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

[Date]

Letter of endorsement

Dear Sir/Madam,

On behalf of University of Namibia, registered at Mandume Ndemufayo Avenue 340, Windhoek 9000, Namibia under [VAT number] and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The University of Namibia (UNAM), through its School of Medicine and the Group for Research in Infectious Diseases (GRID), is an emerging leader in the field of tuberculosis and infectious disease research in Southern Africa. GRID has developed advanced laboratory capacity for targeted sequencing, diagnostics, and surveillance of drug-resistant TB in close partnership with national health authorities and international collaborators. Its research integrates molecular science, epidemiology, geospatial analysis, and social network studies to address pressing public health challenges. The group plays a central role in strengthening Namibia's health research infrastructure, while also contributing to global networks through projects funded by EDCTP and other international partners. By fostering national and regional collaborations and translating research into improved TB control, UNAM demonstrates strong alignment with the Global Health EDCTP3 Joint Undertaking's objectives of capacity building, innovation, and equitable health impact.

UNAM functions as co-applicant (partner number 4) in the AddiCAD 2nd stage proposal which is currently in preparation (Proposal acronym: AddiCAD, proposal number 101248855-2, topic: HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage.) To enable the implementation of the proposed project, the consortium offers to make significant own investments. On project level these amount to a total of € 387 500 (i.e. an additional 18.5% on top of the requested EC contribution) and will be made in the form of in-kind contributions to operational activities (IKOP) as defined in Article 2.8 of the EDCTP3 JU's founding regulation (Single Basic Act, SBA).

Specifically, UNAM's contribution will include the provision of a mobile X-ray unit for the project. UNAM is one of three field sites involved in WP2 "Field evaluation of biomarker tests for diagnosis", and the IKOP contribution will support Task 2.2: Clinical evaluation of AddiCAD.

This commitment will not only allow for more work to be done in the scope of the AddiCAD project, but also have the secondary effect of increasing the budget of Global Health EDCTP3 JU, in accordance with Article 103 of the SBA, and make possible the funding of more research projects.

[Letterhead of the organisation]

We estimate the total value of this in-kind contribution to the AddiCAD project by UNAM to be EUR 56 250.

Commented [AM1]: Please elaborate the costs to better justify this estimation. You could indicate any of the following applicable cases: depreciation over the project use, operating costs (e.g. maintenance) estimated labour costs to operate it, or usage based on costing (cost per hour or scan), etc.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

[Date, name and signature of the authorised representative]